Intratympanale Medikamentenapplikation – Indikationen und Ablauf

 

 Buy Article Permissions and Reprints

Abstract

Neurootologic disorders of the inner ear associated with symptoms such as tinnitus, vertigo, and hearing loss are common and often cause significant distress to affected patients. Treatment options are usually limited. There are now some indications for which intratympanic drug application is a possible treatment option. Intratympanic drug administration is a simple, inexpensive therapy option with few side effects that can be used on an outpatient basis. Therefore, it should not be disregarded when indicated.

Publication History

Article published online:
01 September 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 Piu F, Bishop KM. Local Drug Delivery for the Treatment of Neurotology Disorders. Front Cell Neurosci 2019; 13: 238 DOI: 10.3389/fncel.2019.00238. (PMID: 31213983)
  CrossrefPubMedGoogle Scholar
• 2 El Kechai N, Agnely F, Mamelle E. et al. Recent advances in local drug delivery to the inner ear. Int J Pharm 2015; 494 (01) 83-101 DOI: 10.1016/j.ijpharm.2015.08.015. (PMID: 26260230)
  CrossrefPubMedGoogle Scholar
• 3 Schuknecht HF. Ablation therapy for the relief of Meniere's disease. Laryngoscope 1956; 66 (07) 859-870 DOI: 10.1288/00005537-195607000-00005. (PMID: 13358249)
  CrossrefPubMedGoogle Scholar
• 4 Salt AN, Plontke SK. Pharmacokinetic principles in the inner ear: Influence of drug properties on intratympanic applications. Hear Res 2018; 368: 28-40 DOI: 10.1016/j.heares.2018.03.002. (PMID: 29551306)
  CrossrefPubMedGoogle Scholar
• 5 Juhn SK. Barrier systems in the inner ear. Acta Otolaryngol Suppl 1988; 458: 79-83 DOI: 10.3109/00016488809125107. (PMID: 3245438)
  CrossrefPubMedGoogle Scholar
• 6 Swan EE, Mescher MJ, Sewell WF. et al. Inner ear drug delivery for auditory applications. Adv Drug Deliv Rev 2008; 60 (15) 1583-1599 DOI: 10.1016/j.addr.2008.08.001. (PMID: 18848590)
  CrossrefPubMedGoogle Scholar
• 7 Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999; 109 (07) 1-17 DOI: 10.1097/00005537-199907001-00001. (PMID: 10399889)
  CrossrefPubMedGoogle Scholar
• 8 Chandrasekhar SS, Rubinstein RY, Kwartler JA. et al. Dexamethasone pharmacokinetics in the inner ear: comparison of route of administration and use of facilitating agents. Otolaryngol Head Neck Surg 2000; 122 (04) 521-528 DOI: 10.1067/mhn.2000.102578. (PMID: 10740171)
  CrossrefPubMedGoogle Scholar
• 9 Sutton L, Schartinger V, Url C. et al. Intratympanic steroid use for idiopathic sudden sensorineural hearing loss: current otolaryngology practice in Germany and Austria. Eur Arch Otorhinolaryngol 2018; 275 (05) 1103-1110 DOI: 10.1007/s00405-018-4958-8. (PMID: 29605865)
  CrossrefPubMedGoogle Scholar
• 10 Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. S1-Leitlinie „Hörsturz (Akuter idiopathischer sensorineuraler Hörverlust)“. 01/2014. AWMF-Register-Nr 017/010. Im Internet. www.awmf.org/uploads/tx_szleitlinien/017–010l_S1_Hoersturz_2014–02-verlaengert.pdf
  PubMedGoogle Scholar
• 11 Garavello W, Galluzzi F, Gaini RM. Intratympanic steroid treatment for sudden deafness: a meta-analysis of randomized controlled trials. Otol Neurotol 2012; 33 (05) 724-729 DOI: 10.1097/MAO.0b013e318254ee04. (PMID: 22699982)
  CrossrefPubMedGoogle Scholar
• 12 Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. S3-Leitlinie „Chronischer Tinnitus“. 09/2021. AWMF-Register-Nr. 017/064. Im Internet. www.awmf.org/uploads/tx_szleitlinien 017–064l_S3_Chronischer_Tinnitus_2021–09_1.pdf
  PubMedGoogle Scholar
• 13 Lavigne P, Lavigne F, Saliba I. Intratympanic corticosteroids injections: a systematic review of literature. Eur Arch Otorhinolaryngol 2016; 273 (09) 2271-2278 DOI: 10.1007/s00405-015-3689-3. (PMID: 26100030)
  CrossrefPubMedGoogle Scholar
• 14 Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde Kopf- und Hals-Chirurgie, Deutsche Gesellschaft für Neurologie e.V. (DGN), Deutsche Gesellschaft für Audiologie. S2k-Leitlinie "Vestibuläre Funktionsstörungen“. 03/2021; AWMF-Register-Nr. 017/078. Im Internet. https://register.awmf.org/assets/guidelines/017–078l_S2k_Vestibulaere-Funktionsstoerungen_2021–05.pdf
  PubMedGoogle Scholar
• 15 Magnan J, Ozgirgin ON, Trabalzini F. et al. European Position Statement on Diagnosis, and Treatment of Meniere's Disease. J Int Adv Otol 2018; 14 (02) 317-321 DOI: 10.5152/iao.2018.140818. (PMID: 30256205)
  CrossrefPubMedGoogle Scholar
• 16 Albu S, Chirtes F, Trombitas V. et al. Intratympanic dexamethasone versus high dosage of betahistine in the treatment of intractable unilateral Meniere disease. Am J Otolaryngol 2015; 36 (02) 205-209 DOI: 10.1016/j.amjoto.2014.10.032. (PMID: 25510210)
  CrossrefPubMedGoogle Scholar
• 17 Nevoux J, Barbara M, Dornhoffer J. et al. International consensus (ICON) on treatment of Meniere's disease. Eur Ann Otorhinolaryngol Head Neck Dis 2018; 135 (Suppl. 01) S29-S32 DOI: 10.1016/j.anorl.2017.12.006. (PMID: 29338942)
  CrossrefPubMedGoogle Scholar
• 18 Patel M, Agarwal K, Arshad Q. et al. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Meniere's disease: a randomised, double-blind, comparative effectiveness trial. Lancet 2016; 388: 2753-2762
  CrossrefPubMedGoogle Scholar
• 19 Tjernstrom F, Fransson PA, Kahlon B. et al. PREHAB vs. REHAB – presurgical treatment in vestibular schwannoma surgery enhances recovery of postural control better than postoperative rehabilitation: Retrospective case series. J Vestib Res 2018; 27 (05) 313-325
  CrossrefPubMedGoogle Scholar
• 20 Tarnutzer AA, Bockisch CJ, Buffone E. et al. Pre-habilitation Before Vestibular Schwannoma Surgery-Impact of Intratympanal Gentamicin Application on the Vestibulo-Ocular Reflex. Front Neurol 2021; 12: 633356
  CrossrefPubMedGoogle Scholar
• 21 Van Gompel JJ, Agazzi S, Carlson ML. et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas. Neurosurgery 2018; 82 (02) E52-E4
  CrossrefPubMedGoogle Scholar
• 22 Tjernstrom F, Fransson PA, Kahlon B. et al. Hearing and Vestibular Function After Preoperative Intratympanic Gentamicin Therapy for Vestibular Schwanomma as Part of Vestibular Prehab. Ear Hear 2016; 37 (06) 744-750 DOI: 10.1097/AUD.0000000000000340. (PMID: 27438868)
  CrossrefPubMedGoogle Scholar
• 23 Breslin NK, Varadarajan VV, Sobel ES. Autoimmune inner ear disease: A systematic review of management. Laryngoscope Investig Otolaryngol 2020; 5 (06) 1217-1226 DOI: 10.1002/lio2.508. (PMID: 33364414)
  CrossrefPubMedGoogle Scholar
• 24 Iino Y, Tomioka-Matsutani S, Matsubara A. et al. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris Nasus Larynx 2011; 38 (04) 456-461 DOI: 10.1016/j.anl.2010.11.016. (PMID: 21251776)
  CrossrefPubMedGoogle Scholar
• 25 Chen T, Ashman PE, Bojrab 2nd DI. et al. Diagnosis and management of eosinophilic otitis media: a systematic review. Acta Otolaryngol 2021; 141 (06) 579-587 DOI: 10.1080/00016489.2021.1901985. (PMID: 33825596)
  CrossrefPubMedGoogle Scholar
• 26 Esu Y, Iino Y, Masuda M. et al. Proposal of a Treatment Strategy for Eosinophilic Otitis Media Based on Middle Ear Condition. Otol Neurotol 2018; 39 (08) e671-e678 DOI: 10.1097/MAO.0000000000001912. (PMID: 30113562)
  CrossrefPubMedGoogle Scholar
• 27 Ahmadzai N, Cheng W, Kilty S. et al. Pharmacologic and surgical therapies for patients with Meniere's disease: A systematic review and network meta-analysis. PLoS One 2020; 15 (09) e0237523
  CrossrefPubMedGoogle Scholar
• 28 Postema RJ, Kingma CM, Wit HP. et al. Intratympanic gentamicin therapy for control of vertigo in unilateral Menire's disease: a prospective, double-blind, randomized, placebo-controlled trial. Acta Otolaryngol 2008; 128 (08) 876-880 DOI: 10.1080/00016480701762458. (PMID: 18607963)
  CrossrefPubMedGoogle Scholar
• 29 Stokroos R, Kingma H. Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Meniere's disease: a prospective, double-blind, placebo-controlled, randomized clinical trial. Acta Otolaryngol 2004; 124 (02) 172-175 DOI: 10.1080/00016480410016621. (PMID: 15072419)
  CrossrefPubMedGoogle Scholar
• 30 Masoumi E, Dabiri S, Khorsandi Ashtiani MT. et al. Methylprednisolone versus Dexamethasone for Control of Vertigo in Patients with Definite Meniere's disease. Iran J Otorhinolaryngol 2017; 29 (95) 341-346
  PubMedGoogle Scholar
• 31 Fellmann J, Bachinger D, Dalbert A. et al. Postural stability and handicap of dizziness after preoperative vestibular ablation and vestibular prehabilitation in patients undergoing vestibular schwannoma resection. J Vestib Res 2022; 32 (01) 49-56 DOI: 10.3233/VES-200023. (PMID: 34308917)
  CrossrefPubMedGoogle Scholar
• 32 Amiraraghi N, Gaggini M, Crowther JA. et al. Benefits of pre-labyrinthectomy intratympanic gentamicin: contralateral vestibular responses. J Laryngol Otol 2019; 133 (08) 668-673 DOI: 10.1017/S0022215119001002. (PMID: 31309905)
  CrossrefPubMedGoogle Scholar
• 33 de Cates C, Winters R. Intratympanic Steroid Injection. Treasure Island (FL): StatPearls; 2022
  Google Scholar
• 34 Belhassen S, Saliba I. Pain assessment of the intratympanic injections: a prospective comparative study. Eur Arch Otorhinolaryngol 2012; 269 (12) 2467-2473 DOI: 10.1007/s00405-011-1897-z. (PMID: 22203120)
  CrossrefPubMedGoogle Scholar
• 35 Ata N, Alatas N, Gulluev M. Effect of video-assisted information prior to intratympanic steroid injection on patient anxiety. Am J Otolaryngol 2020; 41 (06) 102689 DOI: 10.1016/j.amjoto.2020.102689. (PMID: 32858371)
  CrossrefPubMedGoogle Scholar
• 36 Lay C. Neue HNO-ärztliche Abrechnungsempfehlungen der Bundesärztekammer 2022. Im Internet. https://abrechnungsstelle.com/hno-abrechnungsempfehlungen/
  PubMedGoogle Scholar